RANCHO CORDOVA, Calif.,
Sept. 8 /PRNewswire/ -- ThermoGenesis
Corp. (Nasdaq: KOOLD), a leading supplier of innovative products
and services that process and store adult stem cells, said today
that findings from the use of concentrated bone marrow-derived stem
cells in orthopedic and Critical Limb Ischemia (CLI) applications
will be presented at the upcoming International Stem Cell Therapy
(ISCT)-Europe regional meeting in
Belgirate, Italy.
The symposium, which takes place on Sunday, September 12, is titled "The Role of Cell
Therapy in Limb Salvage and Spinal Fusion: A Multicenter Experience
with Bone Marrow Derived Mononuclear Cells in Clinical
Practice."
At the symposium, ThermoGenesis will be displaying its offerings
serving the bone marrow stem cell market—the Res-Q™ 60 BMC (Res-Q)
and MXP™ MarrowXpress™ (MXP) Systems. The Company will also be
exhibiting its AXP® AutoXpress™ (AXP) and BioArchive Systems, which
are used for the processing and storage of stem cells from cord
blood.
The ISCT is a global forum and resource for developing and
supporting innovative therapies through communication, education
and training, furthering clinical-based investigation for the
benefit of patients that attracts international experts in the
field of cellular therapy.
The symposium will feature presentations by Dr. James Poser, Executive Vice President of
Regenerative Medicine of Celling Technologies, and Dr. Gilda Cobellis of the Seconda Universta'd
Napoli, in Naples Italy.
Dr. Poser will describe the clinical outcomes achieved using
adult stem cells produced at the point-of-care using the Res-Q
System to prepare concentrates from bone marrow aspirates. Celling
Technologies is a distributor of the Res-Q and MXP Systems in the
U.S.
Dr. Cobellis will discuss the use of adult stem cells derived
using the MXP System with CLI patients as part of the phase II
clinical trial being conducted in Italy. Initial results of the phase I
trial reported earlier this year demonstrated increased perfusion
in treated limbs, which is an important measure of blood
circulation.
"We are looking forward to this symposium and the sharing of the
data from these presentations with ISCT attendees and the value of
the data from this event to increase awareness about our compelling
technology among leaders in regenerative medicine," said
J. Melville Engle, Chief Executive
Officer of ThermoGenesis.
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in
developing and manufacturing automated blood processing systems and
disposable products that enable the manufacture, preservation and
delivery of cell and tissue therapy products. These include:
- The BioArchive® System, an automated cryogenic device, is used
by cord blood stem cell banks in more than 30 countries for
cryopreserving and archiving cord blood stem cell units for
transplant.
- AXP® AutoXpress™ Platform (AXP), a proprietary family of
automated devices that includes the AXP and the MXP™ MarrowXpress™
and companion sterile blood processing disposables for harvesting
stem cells in closed systems. The AXP device is used for the
processing of cord blood. The MXP is used for the preparation of
cell concentrates, including stem cells, from bone marrow aspirates
in the laboratory setting.
- The Res-Q™ 60 BMC (Res-Q), a point-of-care system that is
designed for the preparation of cell concentrates, including stem
cells, from bone marrow aspirates.
- The CryoSeal® FS System, an automated device and companion
sterile blood processing disposable, is used to prepare fibrin
sealants from plasma in about an hour. The CryoSeal FS System is
approved in the U.S. for liver resection surgeries. The CryoSeal FS
System has received the CE-Mark which allows sales of the product
throughout the European community.
This press release contains forward-looking statements, and such
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
involve risks and uncertainties that could cause actual outcomes to
differ materially from those contemplated by the forward-looking
statements. Several factors, including timing of FDA approvals,
changes in customer forecasts, our failure to meet customers'
purchase order and quality requirements, supply shortages,
production delays, changes in the markets for customers' products,
introduction timing and acceptance of our new products scheduled
for fiscal years 2010 and 2011, and introduction of competitive
products and other factors beyond our control, could result in a
materially different revenue outcome and/or in our failure to
achieve the revenue levels we expect for fiscal 2010 and 2011.
A more complete description of these and other risks that
could cause actual events to differ from the outcomes predicted by
our forward-looking statements is set forth under the caption "Risk
Factors" in our annual report on Form 10-K and other reports we
file with the Securities and Exchange Commission from time to time,
and you should consider each of those factors when evaluating the
forward-looking statements.
ThermoGenesis Corp.
|
|
Web site:
http://www.thermogenesis.com
|
|
Contact: Investor
Relations
|
|
+1-916-858-5107, or
|
|
ir@thermogenesis.com
|
|
|
SOURCE ThermoGenesis Corp.
Copyright t. 8 PR Newswire